162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

E.P. Hamilton, Charles L. Shapiro, Valentina Boni, M. Martín Jiménez, Gianluca Del Conte, J. Cortés, Laila Agrawal, H-T. Arkenau, Antoinette R. Tan, Philip R. Debruyne, Anna Minchom, Annemie Rutten, F. Valdes-Albini, Evan Y. Yu, Fumitaka Suto, F-C. Cheng, Bincy Augustine, Bi‐Hua Cheng, Daniel Barrios, S.A. Hurvitz